

CONSONUS
PHARMACY

Consonus Healthcare
consonushealth.com


Plan provided by
Consonus Pharmacy

Road to Recovery: Update




Information current as of 2.19.2021

Road to Recovery:



Current Consonus Stats:




CONSONUS
PHARMACY

Consonus Healthcare
consonushealth.com

Plan provided by
Consonus Pharmacy



National Statistics



LTC Pharmacy Partnership Program Subset

Total Number of Doses Administered in Long-Term Care Facilities

6,070,341

Number of People with 1 or More Doses in Long-Term Care Facilities

4,266,536


Number of People with 2 Doses in Long-Term Care Facilities

1,774,523


CDC | Data as of: Feb 17 2021 6:00am ET | Posted: Feb 17 2021 1:35PM ET

48% Decline in New Cases – After Clinic 1

Phase 2 Federal “Retail” Program: Vaccine Continuity for LTC:



Centers for Disease Control and Prevention
CDC 24/7: Saving Lives, Protecting People™





Vaccines site 


[Advanced Search](#)

[A-Z Index](#)

Vaccines & Immunizations

CDC > COVID-19 Vaccination > Planning & Partnerships > Long-Term Care Pharmacy Partnerships

 COVID-19 Vaccination

Product Info by US Vaccine +

Clinical Care +

Provider Requirements and Support

Training and Education

Recipient Education +

Planning & Partnerships -

COVID-19 Vaccination Program Operational Guidance

Federal Retail Pharmacy Program +

Long-Term Care Pharmacy Partnerships -

Ensuring Access in Long-term Care Facilities

FAQs about Long-Term Care Pharmacy Partnerships

Vaccine Effectiveness Research

Vaccination Toolkits +

Ensuring Access to COVID-19 Vaccine in Long-Term Care Facilities

Long-term care facilities (LTCFs) provide a range of services, including medical and personal care, to adults who are unable to live independently. These types of facilities include, but are not limited to, skilled nursing facilities, nursing homes, assisted living facilities, and other congregate living settings where most people receiving care/supervision are older than 65 years of age. The communal nature of LTCFs and the population served (generally older adults often with underlying medical conditions) puts facility residents at increased risk of SARS-CoV-2 infection and severe illness from COVID-19.

The [Pharmacy Partnership for Long-Term Care \(LTC\) Program](#) is facilitating on-site vaccination of residents and staff at more than 70,000 enrolled LTCFs. Pharmacy partners participating in the program are conducting three on-site vaccination clinics for every enrolled facility. Most clinics provided by this program will likely be completed by the end of March 2021. As the Pharmacy Partnership for LTC program comes to an end, it is important to ensure LTCFs have continued access to COVID-19 vaccine for new or unvaccinated residents and staff.

Ways for Long-term Care Facilities to Continue Receiving COVID-19 Vaccine

LTCF administrators and clinical leadership should consider the following options when making COVID-19 vaccination plans for their facilities.

LTCFs can receive COVID-19 vaccine from an LTC pharmacy that is enrolled as a COVID-19 vaccine provider with their state or territory.	+
LTCFs can receive COVID-19 vaccine from a long-term care (LTC) pharmacy* that is enrolled as a COVID-19 vaccine provider through the Federal Retail Pharmacy Program for COVID-19 Vaccination.	+
LTCFs can receive COVID-19 vaccine by enrolling directly with their state or territory as a COVID-19 vaccine provider.	+

<https://www.cdc.gov/vaccines/covid-19/long-term-care/pharmacy-partnerships-access.html>

Vaccine Continuity Program for LTC

- Change From Clinics to Dispensing
- Moderna Product (Pfizer remains available)
- Federal program, applies to all States
- No Sign Up Required
- CDC Provider Agreement Remains
- Pharmacy Manages Reporting



Stakeholders



The Goal:



Maintain $\geq 70\%$ full vaccination protection within LTC facilities.



Decrease community positivity rates.



Reopen! Bring community and families back together.



Maximize product, minimizing waste

Policy Considerations:



Leveraging
Emergency Use
Authorization for:

- Vaccinators
- Emergency Supply
- Funding


Our Shared Responsibility:



Manage Product



Manage Data



Manage Recipients



CONSONUS
PHARMACY

Consonus Healthcare
consonushealth.com

Plan provided by
Consonus Pharmacy




LTC Continuity Program:



This program may not be for everyone. Other options may be:

- County public health
- Rural access partnerships
- Health systems in your area

Product Similarities:



- mRNA technology
- Highly effective after second dose
- Not interchangeable










- SE/ ADE profile
- Precautions
- Contraindications
- VAERS reporting








- Clinical Screening
- 14 days- other vaccines
- 90- day deferral if received passive antibody therapy

Product Differences:

		moderna™	
	Age	18 yo	16 yo
	Between doses	28 days	21 Days
	Dilution	None, ready to use	Dilute with saline
	Doses/Vial	10	6
	Dose	0.5 ml IM	0.3ml IM
	Storage	Frozen	Ultra-cold

Storage and Handling:

		moderna™	
	Thaw- room temp	1 hr	30 min- 2 hrs (dilute within 2 hrs)
	Refrigerator	30 days	5 days
	Room Temp (unopened vials)	12 hours	2 hours
	In use vials	6 hours after puncture	6 hours after dilution

Clinical Screening and Standing Orders

Moderna COVID-19 Vaccine

Standing Orders for Administering Vaccine
to Persons 18 Years of Age and Older



Note: For more information/guidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

Assess persons 18 years of age and older for vaccination with Moderna COVID-19 Vaccine based on the following criteria:

- No complete 2-dose COVID-19 vaccination history, regardless of brand. If 2 doses of a same-brand or mixed-brand series have been administered, no additional doses are recommended.
 - If the recipient has received 1 previous dose of Moderna COVID-19 Vaccine, a second dose of the same brand should be administered.
- If the vaccine product previously given cannot be determined or is no longer available, any mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.
 - This vaccine is administered in a 2-dose series. Separate doses by at least 28 days, preferably within 6 weeks.*
- Moderna COVID-19 Vaccine should not be administered at the same time as other vaccines. Separate Moderna COVID-19 Vaccine from other vaccines by 14 days before or after the administration of Moderna COVID-19 Vaccine.¹
- Moderna COVID-19 Vaccine should be deferred for at least 90 days for persons who received passive antibody therapy (monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment.

- If the recipient has a history of dermal filler use, advise them to contact their healthcare provider for evaluation if they develop swelling at or near the dermal filler site following vaccination.
- Screen for contraindications and precautions.
 - Contraindications:
 - Severe allergic reaction (e.g., anaphylaxis) to a previous dose or component of either mRNA COVID-19 vaccine.
 - Immediate allergic reaction² of any severity to a previous dose or component of an mRNA COVID-19 vaccine (including polyethylene glycol [PEG]). See Table 1 of vaccine components on page 3.
 - Immediate allergic reaction of any severity to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG).
 - Precautions:
 - History of an immediate allergic reaction to any other vaccine or therapies [excluding subcutaneous immunotherapy of allergies, i.e., "allergy shots"] not related to a component of mRNA COVID-19 vaccines or polysorbate.
 - Moderate to severe acute illness.
- Provide all recipients with a copy of the current federal Emergency Use Authorization (EUA) Fact Sheet for Recipients and Caregivers.
- Prepare to administer the vaccine.

Sex and Weight of Patient	Needle Gauge	Needle Length	Injection Site ¹
Female or male fewer than 130 lbs	22–25	5/8"–1"	Deltoid muscle of arm
Female or male 130–152 lbs	22–25	1"	Deltoid muscle of arm
Female 152–200 lbs	22–25	1–1 1/2"	Deltoid muscle of arm
Male 153–260 lbs	22–25	1–1 1/2"	Deltoid muscle of arm
Female 200+ lbs	22–25	1 1/2"	Deltoid muscle of arm
Male 260+ lbs	22–25	1 1/2"	Deltoid muscle of arm

*Administer the second dose as close to the recommended interval (28 days) as possible. If the second dose is not administered within 6 weeks of the first dose, the series does not need to be restarted. Doses inadvertently administered less than 28 days apart do not need to be repeated.

¹However, mRNA COVID-19 and other vaccines may be administered within a shorter period in situations where the benefits of vaccination are deemed to outweigh the potential unknown risks of vaccine coadministration (e.g., tetanus toxoid-containing vaccination as part of wound management, rabies vaccination for post-exposure prophylaxis, measles or hepatitis A vaccination during an outbreak) or to avoid barriers or delays to mRNA COVID-19 vaccination.

²For the purpose of this guidance, an immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.

¹Alternatively, the anterolateral thigh also can be used.

¹Some experts recommend a 5/8-inch needle for men and women who weigh less than 130 pounds. If used, skin must be stretched tightly (do not bunch subcutaneous tissue).

02/11/2021 CS321571.H

1

Pfizer-BioNTech COVID-19 Vaccine

Standing Orders for Administering Vaccine
to Persons 16 Years of Age and Older



Note: For more information/guidance, please contact the immunization program at your state or local health department or the appropriate state body (e.g., state board of medical/nursing/pharmacy practice).

Purpose

- To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

- Where authorized under state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess and vaccinate persons who meet the criteria in the "Procedure" section below without the need for clinician examination or direct order from the attending provider at the time of the interaction.

Procedure

- Assess persons 16 years of age and older for vaccination with Pfizer-BioNTech COVID-19 Vaccine based on the following criteria:
 - No complete 2-dose COVID-19 vaccination history, regardless of brand. If 2 doses of a same-brand or mixed-brand series have been administered, no additional doses are recommended.
 - If the recipient has received 1 previous dose of Pfizer-BioNTech COVID-19 Vaccine, the second dose of the same brand should be administered.
 - If the vaccine product previously given cannot be determined or is no longer available, any mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose.
 - This vaccine is administered in a 2-dose series. Separate doses by at least 28 days, preferably within 6 weeks.*
- Pfizer-BioNTech COVID-19 Vaccine should not be administered at the same time as other vaccines. Separate Pfizer-BioNTech COVID-19 Vaccine from other vaccines by 14 days before or after the administration of Pfizer-BioNTech COVID-19 Vaccine.¹

- Pfizer-BioNTech COVID-19 Vaccine should be deferred for at least 90 days for persons who received passive antibody therapy (monoclonal antibodies or convalescent plasma) as part of COVID-19 treatment.
- Screen for contraindications and precautions.
 - Contraindications:
 - Severe allergic reaction (e.g., anaphylaxis) to a previous dose or component of either mRNA COVID-19 vaccine.
 - Immediate allergic reaction² of any severity to a previous dose or component of an mRNA COVID-19 vaccine (including polyethylene glycol [PEG]). See Table 1 of vaccine components on page 3.
 - Immediate allergic reaction of any severity to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG).
 - Precautions:
 - History of an immediate allergic reaction to any other vaccine or therapies [excluding subcutaneous immunotherapy of allergies, i.e., "allergy shots"] not related to a component of mRNA COVID-19 vaccines or polysorbate.
 - Moderate to severe acute illness.
- Provide all recipients with a copy of the current federal Emergency Use Authorization (EUA) Fact Sheet for Recipients and Caregivers.
- Prepare to administer the vaccine.

Sex and Weight of Patient	Needle Gauge	Needle Length	Injection Site ¹
Female or male fewer than 130 lbs	22–25	5/8"–1"	Deltoid muscle of arm
Female or male 130–152 lbs	22–25	1"	Deltoid muscle of arm
Female 152–200 lbs	22–25	1–1 1/2"	Deltoid muscle of arm
Male 153–260 lbs	22–25	1–1 1/2"	Deltoid muscle of arm
Female 200+ lbs	22–25	1 1/2"	Deltoid muscle of arm
Male 260+ lbs	22–25	1 1/2"	Deltoid muscle of arm

*Administer the second dose as close to the recommended interval (21 days) as possible. If the second dose is not administered within 6 weeks of the first dose, the series does not need to be restarted. Doses inadvertently administered less than 21 days apart do not need to be repeated.

¹However, mRNA COVID-19 and other vaccines may be administered within a shorter period in situations where the benefits of vaccination are deemed to outweigh the potential unknown risks of vaccine coadministration (e.g., tetanus toxoid-containing vaccination as part of wound management, rabies vaccination for post-exposure prophylaxis, measles or hepatitis A vaccination during an outbreak) or to avoid barriers or delays to mRNA COVID-19 vaccination.

²For the purpose of this guidance, an immediate allergic reaction is defined as any hypersensitivity-related signs or symptoms such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within 4 hours following exposure to a vaccine or medication.

¹Alternatively, the anterolateral thigh also can be used. ¹Some experts recommend a 5/8-inch needle for men and women who weigh less than 130 pounds. If used, skin must be stretched tightly (do not bunch subcutaneous tissue).

02/11/2021 CS321570.H

1



CONSONUS
PHARMACY



Consonus Healthcare
consonushealth.com

Plan provided by
Consonus Pharmacy



ROAD TO
RECOVERY
Ready, Set, Go

Moving from Clinics to Continuity:



Introducing the VaccPack:

- Vaccine
- Syringe (s)
- Alcohol Swabs
- CDC Cards
- Band-Aides
- Diluent (if Pfizer)



Quantity 6




Quantity of 10

Ordering the VaccPack:

- 1 Build your roster of vaccine recipients in the Consonus vaccine app.
- 2 Select date vaccine is to be given
- 3 Send order form to pharmacy indicating the date vaccine is to be given
- 4 Prepare for receipt of vaccine on regular delivery the day prior to your clinic (shippers will receive same day)

Product is to stay in pharmacy packaging until vaccine is given.


Moderna COVID-19 VACCINE ORDER FORM
Please fax completed form to Consonus Pharmacy at (877)-728-8799.

Name of Facility: _____
Send Vaccine to Attention: _____
Phone: _____ Fax: _____

Moderna COVID-19 Vaccine
PRODUCT -- Each completed form will be used to dispense one vial of Moderna COVID-19 vaccine and COVID Vaccine IGL.

Moderna COVID-19 Vaccine Vial
(Contains 50 doses)
Indicated for 18 years and older
NDC: 80717-278-00

Moderna COVID VACCINE KIT (Moderna VaccPack)
Contains:
• 20 x Alcohol Swabs
• 11 x Band-Aid
• 11 x COVID CDC Cards
• 11 x Dose needles/syringe for administration

Roster of Individuals Receiving Vaccination*
To allow for reconciliation in the Consonus Vaccination online application, please indicate the patients who have consented to receiving the vaccine, have been entered into the application, and have been scheduled to receive the vaccination within 6 hours of reconstitution.

Entered into App	Signed Consent	Staff vs Resident	Name	DOS	1 st Dose vs 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose
<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Staff <input type="checkbox"/> Resident			<input type="checkbox"/> 1 st Dose <input type="checkbox"/> 2 nd Dose

Planned date of vaccine administration:** _____
**This date will be used to coordinate vaccine delivery. Vaccine will be sent via regular delivery the night prior to vaccine administration if you have any questions or concerns, please contact Consonus Pharmacy at (866) 698-5120.

Authorized Facility Signature: _____

AUTHORIZED SIGNATURE REQUIRED

Requirement to Give Vaccine:



- Epinephrine in prefilled autoinjector
- Antihistamine (Benadryl)
- Access to call 911



- First Aid Kit



- Stethoscope



- Blood pressure cuff



- Timing device for pulse



- Oxygen



- Pulse Oximeter

Partnership Responsibilities:



- Consent
- EUA to patient
- Clinical screening
- Administration (reconstitution if required)
- Documentation
- Maintaining roster
- Ordering from pharmacy
- Being Accountable for product
- Having emergency supplies on hand



- Program Oversight
- Maintaining supply chain
- Appropriate packaging of VaccPack
- Delivering ordered supply to facility
- Validating roster
- Validate doses administered
- Reporting wasted doses
- Provide Consonus Vaccine APP
- Vaccine administration APP support
- Report mandatory data requirements
- Accountability to CDC
- Accountability state

Documentation:

1


Consent

2

EUA for appropriate vaccine

3

Roster in Consonus Vaccine Administration App




CONSONUS
PHARMACY

Consonus Healthcare
consonushealth.com

Plan provided by
Consonus Pharmacy





Facility Vaccine Administrators

- You will need a vaccinator for the continuity program.

Partnership Ideas

- Collaborate with established relationships
 - Home Health
 - Nurse Practitioner Groups
 - Skilled communities
 - Hospice organizations
 - Agency / per diem nursing
 - Retired Professionals (check state)

Considerations:



New Admission / Staff

- When were they vaccinated?
- What product?
- When are they due for second dose?

Vaccine Verification


- Immunization Information System
- CDC Cards




Process

- Documentation
- Internal policies
- Standing Orders per state
- How do you move from clinic to continuity
- Maintain on call list to reduce waste (within state current phase)


What to Work on Now:



Continue to address vaccine hesitancy



Vaccine Verification



Get internal processes in place



Standing orders




Evaluate if this program is right for your community



Review new admit / staff data

When Do We Get Started?



1

Consonus will contact you with addendum


2

Once you are activated you will receive order forms with acceptance verification.

3

Access to Consonus Vaccine Application

Questions?



- Check our website for the latest information
- FAQ Friday answering your commonly asked questions
- When we have information, you will hear from us
- Next webinar: March 5th